Complementary and alternative medicine application in cancer patients in Iran Nazi NejatAmir RahbarianFatemeh Rafiei Original Article – Clinical Oncology 28 August 2022 Pages: 2271 - 2277
Immunohistochemical analysis of a panel of cancer stem cell markers and potential therapeutic markers in pancreatic ductal adenocarcinoma S. M. Adnan AliYumna AdnanHasnain Ahmed Farooqui Original Article – Clinical Oncology 06 September 2022 Pages: 2279 - 2292
Chemotherapy in combination with anti-PD-1 agents as adjuvant therapy for high-risk oral mucosal melanoma Yunteng WuDongliang WeiWei Guo Original Article – Clinical Oncology 11 September 2022 Pages: 2293 - 2300
Diagnostic role of plasma ORM2 in differentiating prostate cancer from benign prostatic hyperplasia Yuqiu GeBin XuGaoxiang Ma Original Article – Clinical Oncology 05 October 2022 Pages: 2301 - 2310
Clinical characteristics and prognosis of patients with co-existing follicular lymphoma and diffuse large B-cell lymphoma components in rituximab era Yi ChenLuting LuoJianda Hu Original Article – Clinical Oncology 11 October 2022 Pages: 2311 - 2318
Heterozygous germline FLCN mutation in Birt–Hogg–Dubé syndrome with bilateral renal hybrid oncocytic/chromophobe tumor and unilateral renal chromophobe cell carcinoma: a case report Jun LiFan LiuJie Wan Original Article – Clinical Oncology 18 October 2022 Pages: 2319 - 2325
Concurrent chemoradiotherapy combined with nimotuzumab in stage III–IVa nasopharyngeal carcinoma: a retrospective analysis Zhuochen CaiDongni ChenXing Lv Original Article – Clinical Oncology 27 October 2022 Pages: 2327 - 2344
Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis Timothy J. BrownRonac MamtaniYu-Xiao Yang Original Research 02 March 2023 Pages: 2345 - 2354
Predictive role of galectin-3 for immune checkpoint blockades (ICBs) in advanced or metastatic non-small cell lung cancer: a potential new marker for ICB resistance Jung Sun KimSoyeon KimDong-Wan Kim OriginalPaper 17 August 2022 Pages: 2355 - 2365
Lymph node distribution in patients with remnant gastric cancer Alexandre Augusto Ferreira BafuttoOsvaldo Antonio Prado CastroPaulo Kassab Research 21 June 2022 Pages: 2367 - 2374
Safety of sequential immune checkpoint inhibitors after prior immune therapy Muhammad AwidiBrendan ConnellKrishna S. Gunturu Research Open access 21 June 2022 Pages: 2375 - 2382
Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study Lan ZhangXingnong YeJian Huang Research 22 June 2022 Pages: 2383 - 2392
Metabolic pathway-based molecular subtyping of colon cancer reveals clinical immunotherapy potential and prognosis Zhujiang DaiXiang PengJinglue Song Research 22 June 2022 Pages: 2393 - 2416
Comprehensive immunohistochemical analysis of N6-methyladenosine (m6A) writers, erasers, and readers in endometrial cancer Damian J. RalserMateja CondicThore Thiesler Research Open access 22 June 2022 Pages: 2417 - 2424
Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma Shin IshiharaTakeshi IwasakiYoshinao Oda Research 23 June 2022 Pages: 2425 - 2436
Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model Mojgan GhaediForough Golsaz-ShiraziFazel Shokri Research 23 June 2022 Pages: 2437 - 2450
Whole-exome sequencing of Indian prostate cancer reveals a novel therapeutic target: POLQ Febina RavindranAnika JainBibha Choudhary Research 23 June 2022 Pages: 2451 - 2462
Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers Klara DormanMiriam GerckensStefan Holdenrieder Research Open access 23 June 2022 Pages: 2463 - 2474
Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study Tae HataChikara SakaguchiYukio Nagasaka Research 23 June 2022 Pages: 2475 - 2482
The prognostic role of PSMD14 in head and neck squamous cell carcinoma Julia SchnoellAlexandra ScheiflingerBernhard J. Jank Research Open access 25 June 2022 Pages: 2483 - 2490
The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study Jinbin ChenPeiyao XiongLi Xu Research 25 June 2022 Pages: 2491 - 2500
Expression pattern and prognostic potential of histamine receptors in epithelial ovarian cancer Fabian B. T. KrausNicole E. TopalovB. Czogalla Research Open access 25 June 2022 Pages: 2501 - 2511
Combination therapy of doxorubicin and Sildenafil inhibits the growth of pediatric rhabdomyosarcoma Cristian UrlaMatias Julian StagnoEvi Schmid Research Open access 28 June 2022 Pages: 2513 - 2522
Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma Sofya MarchenkoIris PiwonskiEliane Tabea Taube Research Open access 28 June 2022 Pages: 2523 - 2536
Implications for pelvic lymph node irradiation in definitive chemoradiotherapy of node negative muscle invasive bladder cancer based on predictive factors of clinicopathologic discrepancy Arefeh SaeedianAfsaneh Maddah SafaeiEbrahim Esmati Research 28 June 2022 Pages: 2537 - 2542
Role of vascular endothelial growth factor in radiotherapy resistance to esophageal squamous cell carcinoma Xin LiXinyu SuZhengyun Zou Research 29 June 2022 Pages: 2543 - 2550
Chronological development of in-patient oncology in times of COVID-19: a retrospective analysis of hospitalized oncology and COVID-19 patients of a German University Hospital Sebastian GriewingUwe WagnerMatthias Kalder Research Open access 30 June 2022 Pages: 2551 - 2558
TKIs beyond immunotherapy predict improved survival in advanced HCC Samantha ArmstrongTina RoyAiwu Ruth He Research 30 June 2022 Pages: 2559 - 2574
Combined diagnosis of multiparametric MRI-based deep learning models facilitates differentiating triple-negative breast cancer from fibroadenoma magnetic resonance BI-RADS 4 lesions Hao-lin YinYu JiangGuang-wu Lin Research 30 June 2022 Pages: 2575 - 2584
A randomized, open-label, two-cycle, two-crossover phase I clinical trial comparing the bioequivalence and safety of afatinib and Giotrif® in healthy Chinese subjects Guangwen LiuJinling XueHaimiao Yang Research 30 June 2022 Pages: 2585 - 2593
Targeting the (pro)renin receptor in cancers: from signaling to pathophysiological effects Xin OuyangChuanming Xu Review 25 September 2022 Pages: 2595 - 2605
Bioenergy therapies as a complementary treatment: a systematic review to evaluate the efficacy of bioenergy therapies in relieving treatment toxicities in patients with cancer M. HauptmannS. KutschanJ. Dörfler Review Open access 27 September 2022 Pages: 2607 - 2619
BDNF and its signaling in cancer Mohammad MalekanSasan Salehi NezamabadiNima Rezaei Review 29 September 2022 Pages: 2621 - 2636
Ten years of AMNOG from an oncological perspective: new horizons and continuing expansion Arne BartolKatrin DresslerMarco Petschulies Review 01 October 2022 Pages: 2637 - 2645
Heterogeneous molecular behavior in liver tumors (HCC and CCA) of two patients with acute intermittent porphyria Thomas HaverkampOlivia BronischPetro E. Petrides Review 16 October 2022 Pages: 2647 - 2655
Cancer-associated inflammation: pathophysiology and clinical significance Piotr PęczekMonika GajdaAnna M. Badowska-Kozakiewicz Review Open access 19 October 2022 Pages: 2657 - 2672
The impact of smoking on recurrence and progression of non-muscle invasive bladder cancer: a systematic review and meta-analysis Aleksander ŚlusarczykPiotr ZapałaPiotr Radziszewski Review Open access 21 November 2022 Pages: 2673 - 2691
Progress in the treatment of urethral adenocarcinoma Jiamin GuoXiuping LiangJi Ma Review 21 November 2022 Pages: 2693 - 2698
The negative impact of opioids on cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis Mingguang JuZiming GaoKai Li Review 20 December 2022 Pages: 2699 - 2708
Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end? Konstantinos DrougkasKonstantinos KarampinosElias Kotteas Review Open access 24 December 2022 Pages: 2709 - 2734